Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is trending higher in the market today as the company shares are trading 0.29% or 0.005 points up from last closing price of $1.74, reaching $1.745 at last check. Any clue why there is so much of action in the NYMX stock? The share price has risen in 1 of the last 5 days and is up 14.47% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -19,402 shares, and in total 55198 shares valued at $96321 were seen changing hands compared with 74600 shares valued at $129804 recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in NYMX stock for the next couple of days.
Nymox Pharmaceutical Corporation (NYMX) shares have notched a 3-month gain of about 14.47%, but has still advanced 38.93% year to date. By comparison, the stock sank -42.95% over the past 12 months, while it jumped 12.35% over the 1 month. The company’s market cap is around $118.35M, with its short interest ratio standing at 9.6%.
In the current trading session for NYMX, the stock witnessed two major price actions, it rose to a high of $1.75 and was down as much as $1.64 at one point. The high recorded is very low when compared to their 52-week high which is $1.25. The 52-week high is now at -44.23 distance from current price. Their recent low of $3.12 represents a 39.2% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for NYMX is $10.25, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Nymox Pharmaceutical Corporation earned $-0.17 per share in the trailing 12 months and has a P/E ratio of -10.26. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 69.41 and lower compared to the sector’s average of 32.67. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. NYMX also has P/S multiple of 567.39. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 49.47x.
The company recorded an interesting insider purchase transaction by the Director on Jul 09, 2019. A Securities and Exchanges Commission filings show that James George Robinson bought a total of 7,000 NYMX shares that day for a sum of around $11,410. The filings show that the insider stake has now grown to 3,503,550 shares, currently worth $6,113,695. Nymox Pharmaceutical Corporation (NYMX) insiders have acquired 200,000 shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to shares. In total, individual insiders traded 200,000 shares in the business, which makes up 9.261% of 2,159,500 shares that were traded over a year. In the past 12 months, insiders have purchased 371,900 shares while the seller parted with 1,787,600 shares.
NYMX‘s last price was down -6.01% as compared to the average trading price of 50 days recorded at $1.86 while enlarging the period to 200 trading days, the average closing price was $1.66. At present, there are 65.03 million in the total number of common shares owned by the public and among those 29.92 million shares have been available to trade. The percentage of shares being held by the company management was 5.4% while institutions stake was 6%. The company has generated negative returns on equity over the last 12 months (-175.8%). It managed to keep its gross profit margin at 39.5% over the past 12 months.
When assessing the full upside of the NYMX stock, there is another set of technicals that should be looked into and considered. Its -0.23% decline from moving average of $1.75 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.75 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
In the last five years, the EPS of the company has been roughly -4%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about -38.4 over the last five years. The company recently recorded a drop of -80.3%, but this figure is rather unattractive.